Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anandaroop Dasgupta

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|August 7, 2010
Evaluating equivalence and noninferiority trialsAnandaroop Dasgupta, Kenneth A Lawson, James P Wilson
Health Information and Libraries Journal|April 21, 2010
Pharmacists' utilization and interest in usage of personal digital assistants in their professional responsibilitiesAnandaroop Dasgupta, Sujit S Sansgiry, Jeff T Sherer, et al.
Advances in Therapy|September 4, 2025
A Review of the Utilization of Relative Dose Intensity and Dose Delay Factor in Health Technology Appraisals of Oncology Drugs in Solid TumorsAnandaroop Dasgupta, Ankita Kaushik, Shubhram Pandey, et al.
Journal of the American Pharmacists Association : Japha|November 21, 2009
Application of the Extended Technology Acceptance Model in predicting pharmacists' intention to use personal digital assistantsAnandaroop Dasgupta, Sujit S Sansgiry, Jeff T Sherer, et al.
Journal of Health Economics and Outcomes Research|July 10, 2026
Identifying Minimum Threshold Level of Trial Crossover Rates Yielding Nonsignificant Overall Survival Benefit Associated with Cancer Treatments: A Systematic Literature Review of HTA SubmissionsAnandaroop Dasgupta, Ankita Kaushik, Barinder Singh, et al.
Cancers|June 13, 2025
A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Previously Treated HR+/HER- mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) TrialsHope S Rugo, Binghe Xu, Anandaroop Dasgupta, et al.
Journal of Nursing Care Quality|May 5, 2011
Descriptive analysis of workflow variables associated with barcode-based approach to medication administrationAnandaroop Dasgupta, Sujit S Sansgiry, Sheeba M Jacob, et al.
JCO Global Oncology|March 14, 2024
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and JapanTiciana A Leal, Anandaroop Dasgupta, Dominick Latremouille-Viau, et al.
JCO Global Oncology|September 20, 2024
Real-World Outcomes of First-Line Treatment With Anti-PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United StatesStephen V Liu, Anandaroop Dasgupta, Dominick Latremouille-Viau, et al.
Therapeutic Advances in Medical Oncology|March 17, 2025
Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trialsOleg Gluz, Binghe Xu, Rita Nanda, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|August 7, 2010
Evaluating equivalence and noninferiority trialsAnandaroop Dasgupta, Kenneth A Lawson, James P Wilson
Health Information and Libraries Journal|April 21, 2010
Pharmacists' utilization and interest in usage of personal digital assistants in their professional responsibilitiesAnandaroop Dasgupta, Sujit S Sansgiry, Jeff T Sherer, et al.
Advances in Therapy|September 4, 2025
A Review of the Utilization of Relative Dose Intensity and Dose Delay Factor in Health Technology Appraisals of Oncology Drugs in Solid TumorsAnandaroop Dasgupta, Ankita Kaushik, Shubhram Pandey, et al.
Journal of the American Pharmacists Association : Japha|November 21, 2009
Application of the Extended Technology Acceptance Model in predicting pharmacists' intention to use personal digital assistantsAnandaroop Dasgupta, Sujit S Sansgiry, Jeff T Sherer, et al.
Journal of Health Economics and Outcomes Research|July 10, 2026
Identifying Minimum Threshold Level of Trial Crossover Rates Yielding Nonsignificant Overall Survival Benefit Associated with Cancer Treatments: A Systematic Literature Review of HTA SubmissionsAnandaroop Dasgupta, Ankita Kaushik, Barinder Singh, et al.
Cancers|June 13, 2025
A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Previously Treated HR+/HER- mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) TrialsHope S Rugo, Binghe Xu, Anandaroop Dasgupta, et al.
Journal of Nursing Care Quality|May 5, 2011
Descriptive analysis of workflow variables associated with barcode-based approach to medication administrationAnandaroop Dasgupta, Sujit S Sansgiry, Sheeba M Jacob, et al.
JCO Global Oncology|March 14, 2024
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and JapanTiciana A Leal, Anandaroop Dasgupta, Dominick Latremouille-Viau, et al.
JCO Global Oncology|September 20, 2024
Real-World Outcomes of First-Line Treatment With Anti-PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United StatesStephen V Liu, Anandaroop Dasgupta, Dominick Latremouille-Viau, et al.
Therapeutic Advances in Medical Oncology|March 17, 2025
Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trialsOleg Gluz, Binghe Xu, Rita Nanda, et al.
Pageof 2